MAPT and corticobasal degeneration disorder: However, the concept of targeting alterations in tau processing as a fluid biomarker may not only have implications for AD, as a recent study showed that tau peptides in the microtubule-binding region (MTBR-tau275 and MTBR-tau282) when used in a ratio with a t-tau-like peptide were able to discriminate individuals with corticobasal degeneration (CBD), certain frontotemporal lobar degeneration (FTLD)-MAPT variants and AD, when compared with other tauopathies and clinical mimics [37].